Aethlon Medical, Inc. (AEMD)
| Market Cap | 31.28M |
| Revenue (ttm) | 620,187 |
| Net Income (ttm) | -5.78M |
| Shares Out | 12.07M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $2.67 |
| Previous Close | $2.55 |
| Change ($) | 0.12 |
| Change (%) | 4.71% |
| Day's Open | 2.60 |
| Day's Range | 2.57 - 2.77 |
| Day's Volume | 568,926 |
| 52-Week Range | 1.23 - 4.34 |
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflamm...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflamm...
Aethlon Medical (AEMD) news for Wednesday concerning the progress in an EFS for one of its medical devices has AEMD stock soaring higher. The post Aethlon Medical News Alert: Why AEMD Stock Is...
SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening disea...
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2021 Results - Earnings Call Transcript
SAN DIEGO, Oct. 28, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threateni...
SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue f...
SAN DIEGO, Aug. 27, 2020 /PRNewswire/ -- Aethlon Medical, Inc.
Aethlon Medical, Inc. (AEMD) CEO Timothy Rodell on Q1 2021 Results - Earnings Call Transcript
SAN DIEGO, Aug. 11, 2020 /PRNewswire/ -- Aethlon Medical, Inc.
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc.
Aethlon Medical, Inc. (AEMD) CEO Timothy Rodell on Q4 2020 Results - Earnings Call Transcript
SAN DIEGO, June 25, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threateni...
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflam...
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q3 2020 Results - Earnings Call Transcript
The story that has dominated this past week is that China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.
China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.
Shares of several vaccine makers were on the rise Tuesday following reports of a spreading coronavirus outbreak in Asia.
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2020 Results - Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q1 2020 Results - Earnings Call Transcript
About AEMD
Aethlon Medical, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studi... [Read more...]
| Industry Medical Devices | |
| CEO Timothy Rodell | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol AEMD |
Financial Performance
In 2019, AEMD's revenue was $650,187, an increase of 183.15% compared to the previous year's $229,625. Losses were -$6.37 million, 2.89% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for AEMD stock is "Buy" and the 12-month stock price forecast is 7.00.